Evidence map›Paper›PMID 36895328›Full record

ArticleBritish journal of biomedical science2023

SPHINX-Based Combination Therapy as a Potential Novel Treatment Strategy for Acute Myeloid Leukaemia.

Chigeru Wodi, Tareg Belali, Ruth Morse, Sean Porazinski, Michael Ladomery

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of biomedical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Chigeru WodiCentre for Research in Bioscience, Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom.
Tareg BelaliCentre for Research in Bioscience, Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom.
Ruth MorseCentre for Research in Bioscience, Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom.
Sean PorazinskiGarvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Michael LadomeryCentre for Research in Bioscience, Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom.
University of the West of England · GBSt Vincent's Clinic · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsApoptosisAzacitidineDrug Resistance, NeoplasmHumansImatinib MesylateProtein Serine-Threonine KinasesAntineoplastic AgentsAzacitidineImatinib MesylateProtein Serine-Threonine KinasesSRPK1 protein, humanacute myeloid leukemiaalternative splicingSPHINXsplice factor kinasesSRPK1

Identifiers

PMID36895328
PMCPMC9988938
OpenAlexW4321459284

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.